Loading
Loading
Your feedback directly shapes Sporos.
Sign in to track your feedback history
Provides that an agreement resolving a patent infringement claim, in connection with the sale of a pharmaceutical product, is to be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value.
Introduced
Feb 28, 2025
Last Action
Mar 11, 2025
Session
RI 2025
Sponsors
10 primary · 0 co
03/11/2025 Committee recommended measure be held for further study
03/07/2025 Scheduled for hearing and/or consideration (03/11/2025)
02/28/2025 Introduced, referred to House Judiciary